Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supernus Aims For IPO Backed By Unusual Royalty Deal

This article was originally published in Start Up

Executive Summary

CNS-focused Supernus Pharmaceuticals Inc. filed its intent to go public just before Christmas, making it the last biopharma to file in a year that ended with some cautious optimism about the IPO market. But Supernus stands apart from the year’s success stories in that most of its $157 million in financing in five years of existence has been non-dilutive. Thus, even if the company trims its offer price, investors are poised for a satisfying payoff.
Advertisement

Related Content

Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
US Biopharma IPOs: Market's Rally Passes Them By
US Biopharma IPOs: Market's Rally Passes Them By
Baked-In Goodness: Shire Buys New River for $2.6 Billion
Baked-In Goodness: Shire Buys New River for $2.6 Billion
Shire: Remodeling Specialty Pharma
Shire: Remodeling Specialty Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel